PDMI NEWS: Friday March 5, 2010, 8:00 am

Paradigm Medical Industries, Inc. (PINKSHEETS: PDMI) announced today that it has been notified by its Italian partner, Costruzione Strumenti Oftalmici (CSO), that all necessary documents have been completed and submitted to the United States Food and Drug Administration (FDA) for the Retimax™, also known as the Paramax. Paradigm is the exclusive representative for this significant new product in the U.S. market. "This new innovative device offers the earliest detection of glaucoma currently available and will be an excellent addition to Paradigm's glaucoma diagnostic products," said Stephen Davis, Paradigm's President and Chief Executive Officer.

The Paramax (as it will be known in the United States) represents the third product that Paradigm represents for CSO. Paradigm also represents CSO's impressive corneal topographer, to be known in the U.S. as the Paravue 300, and CSO's corneal topographer with Scheimpflug rotating camera, to be known in the U.S. as the Surveyor 500. The Surveyor 500 with the Scheimpflug camera allows for the complete analysis of the entire cornea and anterior segment of the eye. Paradigm plans to begin active promotion of the Paravue 300 and the Surveyor 500 and will actively promote the Paramax immediately after it has received FDA approval.